Danaher Corporation (DHR) reported better-than-expected third-quarter financial results, with adjusted EPS of $1.89 surpassing analyst estimates of $1.72 and revenue reaching $6.05 billion against a $6.01 billion forecast, attributed to strong bioprocessing momentum and Cepheid's respiratory revenue. Despite this positive performance, the company's shares experienced a slight decline of 0.4%, though Danaher maintained its full-year 2025 adjusted EPS guidance of $7.70-$7.80 and projected low-single-digit core revenue growth. Following the earnings, analysts from Barclays and TD Cowen reiterated positive ratings and raised their price targets for DHR.
Danaher Corporation (DHR) delivered a robust third-quarter performance, with adjusted earnings per share (EPS) of $1.89 significantly surpassing the analyst consensus of $1.72 by 9.82%. Quarterly revenue also exceeded expectations, reaching $6.05 billion against a $6.01 billion forecast. This outperformance was attributed to strong momentum in its bioprocessing business and better-than-anticipated respiratory revenue from Cepheid. Despite the strong financial beat, DHR shares experienced a modest 0.4% decline to $219.87 post-announcement. The company maintained its full-year 2025 adjusted EPS guidance of $7.70 to $7.80, which aligns closely with analyst estimates of $7.78. Management also projected low-single-digit core revenue growth for full-year 2025, indicating a stable but moderate outlook. Following the earnings report, several analysts reiterated positive sentiment and raised their price targets for DHR. Barclays maintained an Overweight rating, increasing its target from $225 to $250, while TD Cowen maintained a Buy rating and raised its target from $250 to $260. This suggests continued confidence in DHR's long-term prospects despite the immediate slight share price dip.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Overall Sentiment
strongly positive
Sentiment Score
0.75
Ticker Sentiment
